KOL Identification

A top-10 biopharma wanted to assess how the biomarker testing and treatment landscape would change, and the potential impact on the use of their drug, in response to a recent approval of a new competing cancer therapy approved in earlier lines of treatment

A top-10 scientific service provider wanted to quantify the size of the CGT services market and understand trends within

A multi-billion dollar life science company needed pre diligence on a potential acquisition target

A startup wanted to understand how customers could use its cutting-edge technology and which applications to target for further development

A leading diagnostic company wanted an assessment of the future market landscape for low-throughput (LT) molecular diagnostic (MDx) testing to develop a long-term platform strategy to address the future needs of this market

A large multi-national diagnostic company was interested in understanding the market landscape and potential strategy for the decentralization of NIPT in the U.S.